DMAC241220C7500
- 0.00
- 0.000.00%
DiaMedica Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Analyst Ratings
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)
Diamedica Therapeutics Initiated at Buy by HC Wainwright & Co.
H.C. Wainwright Initiates DiaMedica Therapeutics(DMAC.US) With Buy Rating, Announces Target Price $7
DiaMedica Therapeutics Analyst Ratings